Jeffrey Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6864901/publications.pdf

Version: 2024-02-01



IFFEDEV RDOWN

#	Article	IF	CITATIONS
1	Launching PCORnet, a national patient-centered clinical research network. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 578-582.	2.2	491
2	Use of antidepressant medications during pregnancy: a multisite study. American Journal of Obstetrics and Gynecology, 2008, 198, 194.e1-194.e5.	0.7	321
3	Developing the Sentinel System — A National Resource for Evidence Development. New England Journal of Medicine, 2011, 364, 498-499.	13.9	308
4	The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. EGEMS (Washington, DC), 2017, 2, 2.	2.0	300
5	Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiology and Drug Safety, 2012, 21, 1-10.	0.9	283
6	Design considerations, architecture, and use of the Miniâ€ 5 entinel distributed data system. Pharmacoepidemiology and Drug Safety, 2012, 21, 23-31.	0.9	204
7	Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events. Medical Care, 2007, 45, S89-S95.	1.1	195
8	Distributed Health Data Networks. Medical Care, 2010, 48, S45-S51.	1.1	195
9	The U.S. Food and Drug Administration's Miniâ€5entinel program: status and direction. Pharmacoepidemiology and Drug Safety, 2012, 21, 1-8.	0.9	155
10	Design of a National Distributed Health Data Network. Annals of Internal Medicine, 2009, 151, 341.	2.0	148
11	Graphical Depiction of Longitudinal Study Designs in Health Care Databases. Annals of Internal Medicine, 2019, 170, 398.	2.0	140
12	The FDA Sentinel Initiative — An Evolving National Resource. New England Journal of Medicine, 2018, 379, 2091-2093.	13.9	137
13	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and Drug Safety, 2017, 26, 1018-1032.	0.9	126
14	Early detection of adverse drug events within populationâ€based health networks: application of sequential testing methods. Pharmacoepidemiology and Drug Safety, 2007, 16, 1275-1284.	0.9	112
15	Data Quality Assessment for Comparative Effectiveness Research in Distributed Data Networks. Medical Care, 2013, 51, S22-S29.	1.1	112
16	Four Health Data Networks Illustrate The Potential For A Shared National Multipurpose Big-Data Network. Health Affairs, 2014, 33, 1178-1186.	2.5	106
17	Transparent Reporting of Data Quality in Distributed Data Networks. EGEMS (Washington, DC), 2017, 3, 7.	2.0	84
18	Drug safety data mining with a treeâ€based scan statistic. Pharmacoepidemiology and Drug Safety, 2013, 22, 517-523.	0.9	72

JEFFREY BROWN

#	Article	IF	CITATIONS
19	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health, 2017, 20, 1009-1022.	0.1	70
20	Cost effectiveness of topiramate in the prevention of migraines in the United States: an update. Managed Care Interface, 2006, 19, 31-8.	0.2	66
21	Evaluating Foundational Data Quality in the National Patient-Centered Clinical Research Network (PCORnet®). ECEMS (Washington, DC), 2018, 6, 3.	2.0	65
22	MDPHnet: Secure, Distributed Sharing of Electronic Health Record Data for Public Health Surveillance, Evaluation, and Planning. American Journal of Public Health, 2014, 104, 2265-2270.	1.5	59
23	Confounding Adjustment in Comparative Effectiveness Research Conducted Within Distributed Research Networks. Medical Care, 2013, 51, S4-S10.	1.1	55
24	Use of electronic health records to support a public health response to the COVID-19 pandemic in the United States: a perspective from 15 academic medical centers. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 393-401.	2.2	54
25	Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiology and Drug Safety, 2008, 17, 240-247.	0.9	53
26	Identifying health outcomes in healthcare databases. Pharmacoepidemiology and Drug Safety, 2015, 24, 1009-1016.	0.9	51
27	A Survey of Informatics Platforms That Enable Distributed Comparative Effectiveness Research Using Multi-institutional Heterogenous Clinical Data. Medical Care, 2012, 50, S49-S59.	1.1	44
28	MR Volumetry of Brain and CSF in Fetuses Referred for Ventriculomegaly. American Journal of Roentgenology, 2007, 189, 145-151.	1.0	43
29	Data Extraction And Management In Networks Of Observational Health Care Databases For Scientific Research: A Comparison Among EU-ADR, OMOP, Mini-Sentinel And MATRICE Strategies. EGEMS (Washington, DC), 2017, 4, 2.	2.0	43
30	Clinical research data warehouse governance for distributed research networks in the USA: a systematic review of the literature. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 730-736.	2.2	42
31	Query Health: standards-based, cross-platform population health surveillance. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 650-656.	2.2	41
32	Cost-Effectiveness of Topiramate in Migraine Prevention: Results From a Pharmacoeconomic Model of Topiramate Treatment. Headache, 2005, 45, 1012-1022.	1.8	40
33	Early adverse drug event signal detection within populationâ€based health networks using sequential methods: key methodologic considerations. Pharmacoepidemiology and Drug Safety, 2009, 18, 226-234.	0.9	38
34	Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiology and Drug Safety, 2012, 21, 1350-1358.	0.9	38
35	A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiology and Drug Safety, 2008, 17, 1226-1234.	0.9	37
36	Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Supportive Care in Cancer, 2020, 28, 2553-2562.	1.0	33

JEFFREY BROWN

#	Article	IF	CITATIONS
37	Electronic clinical laboratory test results data tables: lessons from Mini‧entinel. Pharmacoepidemiology and Drug Safety, 2014, 23, 609-618.	0.9	30
38	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiology and Drug Safety, 2020, 29, 3-7.	0.9	28
39	Software-Enabled Distributed Network Governance: The PopMedNet Experience. EGEMS (Washington,) Tj ETQq1	1 0,78431 2.0	4 rgBT /Ove 28
40	Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic. Pharmaceutics, 2013, 5, 179-200.	2.0	27
41	A <scp>COVID</scp> â€19â€ready public health surveillance system: The Food and Drug Administration's Sentinel System. Pharmacoepidemiology and Drug Safety, 2021, 30, 827-837.	0.9	26
42	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. Npj Digital Medicine, 2021, 4, 170.	5.7	25
43	Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 109-117.	2.5	24
44	Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program. JAMA Internal Medicine, 2013, 173, 817.	2.6	24
45	Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 793-797.	2.2	24
46	Active Influenza Vaccine Safety Surveillance. Medical Care, 2009, 47, 1251-1257.	1.1	23
47	Migraine Frequency and Health Utilities: Findings from a Multisite Survey. Value in Health, 2008, 11, 315-321.	0.1	22
48	Validation of claimsâ€based algorithms for identification of highâ€grade cervical dysplasia and cervical cancer. Pharmacoepidemiology and Drug Safety, 2013, 22, 1239-1244.	0.9	21
49	Developing realâ€world evidence from realâ€world data: Transforming raw data into analytical datasets. Learning Health Systems, 2022, 6, e10293.	1.1	21
50	Success Of Program Linking Data Sources To Monitor H1N1 Vaccine Safety Points To Potential For Even Broader Safety Surveillance. Health Affairs, 2012, 31, 2518-2527.	2.5	17
51	A Query Workflow Design to Perform Automatable Distributed Regression Analysis in Large Distributed Data Networks. EGEMS (Washington, DC), 2018, 6, 11.	2.0	16
52	Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans. Pharmacoepidemiology and Drug Safety, 2008, 17, 1137-1141.	0.9	15
53	Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools. Pharmacoepidemiology and Drug Safety, 2018, 27, 332-339.	0.9	15
54	Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. Pharmacoepidemiology and Drug Safety, 2014, 23, 839-848.	0.9	14

Jeffrey Brown

#	Article	IF	CITATIONS
55	The FDA MyStudies app: a reusable platform for distributed clinical trials and real-world evidence studies. JAMIA Open, 2021, 3, 500-505.	1.0	14
56	Evidence generation from healthcare databases: recommendations for managing change. Pharmacoepidemiology and Drug Safety, 2016, 25, 749-754.	0.9	13
57	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate â€~Real World' Evidence of Comparative Effectiveness and Safety. Drug Safety, 2019, 42, 1297-1309.	1.4	13
58	Aggregating Electronic Health Record Data for COVID-19 Research—Caveat Emptor. JAMA Network Open, 2021, 4, e2117175.	2.8	13
59	Methods for examining data quality in healthcare integrated data repositories. , 2018, , .		10
60	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. Drug Safety, 2020, 43, 1-5.	1.4	10
61	Near realâ€time adverse drug reaction surveillance within populationâ€based health networks: methodology considerations for data accrual. Pharmacoepidemiology and Drug Safety, 2013, 22, 488-495.	0.9	9
62	Medical Product Safety Surveillance. Epidemiology, 2013, 24, 692-699.	1.2	8
63	Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care. Journal of the American Society of Nephrology: JASN, 2020, 31, 2506-2516.	3.0	8
64	Health outcomes coding trends in the US Food and Drug Administration's Sentinel System during transition to International Classification of Diseasesâ€10 coding system: A brief review. Pharmacoepidemiology and Drug Safety, 2021, 30, 838-842.	0.9	8
65	Use of a mobile app to capture supplemental health information during pregnancy: Implications for clinical research. Pharmacoepidemiology and Drug Safety, 2021, , .	0.9	7
66	Collaborating on Data, Science, and Infrastructure: The 20-Year Journey of the Cancer Research Network. EGEMS (Washington, DC), 2019, 7, 7.	2.0	6
67	Big Data in the Assessment of Pediatric Medication Safety. Pediatrics, 2020, 145, .	1.0	6
68	Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detection. Journal of Clinical Epidemiology, 2010, 63, 407-411.	2.4	5
69	Impact of exposure accrual on sequential postmarket evaluations: a simulation study. Pharmacoepidemiology and Drug Safety, 2011, 20, 1184-1191.	0.9	5
70	Considerations for using distributed research networks to conduct aspects of randomized trials. Contemporary Clinical Trials Communications, 2020, 17, 100515.	0.5	5
71	Utilization patterns and characteristics of users of biologic antiâ€inflammatory agents in a large, US commercially insured population. Pharmacology Research and Perspectives, 2021, 9, e00708.	1.1	5
72	Characteristics of new adult users of mepolizumab with asthma in the USA. BMJ Open Respiratory Research, 2021, 8, e001003.	1.2	5

JEFFREY BROWN

#	Article	IF	CITATIONS
73	Orphan Therapies: Making Best Use of Postmarket Data. Journal of General Internal Medicine, 2014, 29, 745-751.	1.3	4
74	Cancer Screening Results and Follow-up Using Routinely Collected Electronic Health Data: Estimates for Breast, Colon, and Cervical Cancer Screenings. Journal of General Internal Medicine, 2019, 34, 341-343.	1.3	4
75	A Data Element-Function Conceptual Model for Data Quality Checks. EGEMS (Washington, DC), 2019, 7, 17.	2.0	4
76	Antibiotic dispensing following pediatric visits in the US emergency departments and outpatient settings from 2006 to 2016. Pharmacology Research and Perspectives, 2019, 7, e00512.	1.1	3
77	Crossâ€Network Directory Service: Infrastructure to enable collaborations across distributed research networks. Learning Health Systems, 2019, 3, e10187.	1.1	3
78	Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1156-1161.	0.5	2
79	Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 417-490.	0.5	2
80	Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product. Drugs - Real World Outcomes, 2021, 8, 125-130.	0.7	2
81	The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. Pharmacoepidemiology and Drug Safety, 2017, 26, 446-458.	0.9	1
82	Spending and Quality of Care for Medicare Beneficiaries in Massachusetts. JAMA - Journal of the American Medical Association, 2013, 310, 2674.	3.8	0
83	Response to "Externally Controlled Trials: Are We There Yet?― Clinical Pharmacology and Therapeutics, 2020, 108, 920-920.	2.3	0
84	PopMedNet: A scalable and extensible open-source informatics platform designed to facilitate the implementation and operation of distributed health data networks. Journal of Open Source Software, 2022, 7, 4062.	2.0	0